TP53 and acute myeloid leukemia: Boettcher et al. showed in engineered human cell lines that gain-of-function (GOF) activities might be dispensable in AML [94], and that the dominant-negative expression (DNE) of TP53 mutants appeared to be the main driver of leukemogenesis, leading to p53 inactivation.